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Abstract
Background: Phthalates are excipients in drug formulations. However, concerns have been raised about the effects of
particular phthalates on reproduction and development. As a result the EMA has introduced guidelines for permitted
daily exposure (PDE) limits for certain phthalates. Therefore, the objective of this study was to identify UK licensed
medicines that contain the relevant phthalates and determine if they fall within the recommended PDE.
Methods: The eMC was used to identify which UK licensed medicines contain the phthalates in question. Companies
were then contacted for information on the phthalate levels in their products, which was compared with the PDE
recommended by the EMA.
Results: The eMC search revealed that 54 medicines contained at least one of the phthalates in question. However,
only six medicines, namely Asacol 800 mg MR (Warner Chilcott UK), Epilim 200 Gastro-resistant tablets (Sanofi),
Prednisolone 2.5 mg and 5 mg Gastro-resistant tablets (Actavis UK), Vivotif (Crucell Italy S.r.l), and Zentiva 200 mg
Gastro-resistant tablets (Winthrop Pharmaceuticals UK), were identified as containing levels that exceeded the
recommended PDE.
Conclusions: These findings indicate that very few UK licensed medicines will be affected by the proposed EMA
guidelines. For those medicines identified as exceeding recommendations, these findings highlight the need to
instigate a risk-benefit review.
Keywords: Environmental exposure, Phthalic acids, Dibutyl Phthalate (DBP), Diethyl Phthalate (DEP),
Polyvinylacetate Phthalate (PVAP), Excipients, Phthalate
Background
Phthalates are synthetic chemical esters of phthalic acid,
that are broadly divided into low molecular weight (LMW)
phthalates, which include the likes of dibutyl phthalate
(DBP), diethyl phthalate (DEP) and dimethyl phthalate
(DMP); high molecular weight (HMW) phthalates, which
encompass butylbenzyl phthalate (BBzP), di-2-ethylhexyl
phthalate (DEHP), di-isodecyl phthalate (DiDP), di-isononyl
phthalate (DiNP) and di-n-octyl phthalate (DnOP); and
phthalate polymers, such as cellulose acetate phthalate
(CAP), hydroxypropyl methylcellulose phthalate (HPMCP)
and polyvinyl acetate phthalate (PVAP). They confer
numerous properties, including those as a lubricant, a solv-
ent, a softener and a plasticizer, which increases flexibility
and durability. Consequently they were once widely found
in a variety of consumer products, thus leading to ubiqui-
tous daily exposure [1].
However, concerns have been raised regarding the effects
of certain phthalates on reproduction and development.
These worries predominantly stem from their endocrine-
disrupting properties, and associated anti-androgen impli-
cations. They have been well documented pre-clinically,
particularly in the rat, where prenatal exposure to particular
phthalates has affected male and female offspring, with re-
spect to numerous parameters including anogenital dis-
tance (AGD), gender ratio, nipple retention, ear and eye
unfolding, vaginal opening and foetal weight and viability
[2–4]. In addition, it has been demonstrated that their
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effects are additive when combined with each other, as well
as, different classes of anti-androgen chemicals [5]. In fact
the endocrine-disrupting effects of phthalates in the rat are
so robust that within endocrinology laboratories, phthalates
are often used as tools to induce testicular dysgenesis syn-
drome (TDS). By contrast to the preclinical arena, where
there are vast studies evaluating the health implications of
phthalates, too many to discuss within the scope of this art-
icle, clinical data are few and far between. Those that exist
come from human association studies and suggest that pre-
natal exposure to certain phthalates reduces the AGD
amongst male offspring, possibly indicative that it compro-
mises virilisation [6, 7]. There is also evidence to suggest
that prenatal exposure reduces masculine-play behaviour
amongst pre-school males [8]. Furthermore, evaluation of
phthalate exposure during adulthood demonstrates that it
may contribute to both a reduction in the levels of circulat-
ing steroid hormones and sperm quality in males, as well as
reduced fertility, in both males and females [9–12].
Whilst it is acknowledged that clinical data are limited
and, in some cases inconsistent, regulatory bodies affiliated
with consumer goods that contain phthalates deemed it
necessary to take precautionary measures. Consequently,
guidelines have been developed aimed at reducing exposure
to certain phthalates in cosmetics [13], childcare articles
[14], plastics in contact with food [15] and medical devices
[16–18]. Certain medicines represent a source of phthalate
exposure, where they exist as excipients, that is, inactive
components. Since phthalates are insoluble in acidic envi-
ronments and soluble in neutral and alkaline conditions,
they are commonly used as plasticizing agents in gastro-
resistant film coatings for tablets, capsules, beads and gran-
ules, thus enabling targeted delivery of active ingredient(s)
to the more alkaline environment of the intestine. This is
likely the reason that drugs for gastrointestinal indications
have been identified as particularly high sources of phthal-
ate exposure [19, 20]. Furthermore, animal and human
pharmacokinetic studies have shown that LMW phthalates,
such as DBP and DEP, have near complete intestinal ab-
sorption, with 78–90 % of the administered dose excreted
in the urine within 24 h [21–23]. However, for the HMW
phthalates CAP, PVAP and HPMCP, there is currently no
pharmacokinetic data available.
Accordingly in 2012, the Food and Drug Administration
(FDA) also developed guidelines aimed at minimising
phthalate exposure in products regulated by the Centre
for Drug Evaluation and Research (CDER) [24]. Specific-
ally, the Agency determined that there is evidence that ex-
posure to DBP and DEHP from pharmaceuticals presents
a potential risk of developmental and reproductive tox-
icity. While the Agency recognised that drug products
may carry inherent risks, it stated that DBP and DEHP are
used as excipients, and safer alternatives are available.
Therefore, the Agency recommends that DBP and DEHP
be avoided as excipients in CDER-regulated drug and
biologic products [24]. In line with the FDA, the EMA’s
Committee for Medicinal Products for Human Use
(CHMP) is currently drafting its own recommendations
on the use of phthalates as excipients in human medi-
cinal products [1]. Whilst these guidelines have yet to
be finalised, they are expected to propose permitted
daily exposures (PDE) of ≤ 0.01, 4 and 2 mg/kg for DBP,
DEP and PVAP, respectively and are predicted to be
enforced in 2015. For existing authorised medicinal
products, the EMA is proposing to set a time limit of
three years (after coming into force of the final guideline)
for the implementation of formulation changes and conse-
quential regulatory applications, as necessary. Ahead of
their implementation, the authors of this study aimed to
identify which United Kingdom (UK)- licensed drugs are
likely to be affected by the proposed EMA guidelines, in
order to help prepare for potential consequences.
Methods
The first step in this process was to identify which UK li-
censed medicines contain at least one of the three precau-
tionary phthalates, DBP, DEP and PVAP, named in the
draft EMA guidelines. The electronic Medicines Compen-
dium (eMC) [25] was deemed an effective way to find
these medicines, as it contains up to date information
about most medicines licensed in the UK and is checked
and approved by either the Medicines and Healthcare
products Regulatory Agency (MHRA) or the EMA. The
eMC was utilised via the algorithm depicted in Fig. 1.
The eMC provided the medical information email ad-
dress associated with each medicine found to contain
the precautionary phthalates. The next stage was to con-
tact the companies affiliated with each of the medicines
identified as containing the precautionary phthalates. In
many cases, a single medical information address was af-
filiated with numerous products, thus it was only neces-
sary to issue emails to 28 different medical information
companies, requesting information about the maximum
daily exposure of the relevant phthalate(s) in their prod-
uct(s). Twenty-seven companies were contacted using
the medical information email address provided by the
eMC and one was contacted by an online enquiry form.
The companies were made aware of the proposed EMA
guidelines and their phthalate containing product(s) was
identified together with a request for information on the
maximum daily exposure of the affiliated phthalate(s).
Results
The eMC search to identify UK medicines containing at
least one of the three precautionary phthalates, DBP, DEP
and PVAP, named in the draft EMA guidelines, produced
50 hits (information correct as of 9th June 2014), one of
which was deemed a false positive because the drug was
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listed as discontinued (Maxolon SR 15 mg Capsules). The
remaining 49 hits, consisted of 54 branded medicines, five
of which contained DBP alone, 17 contained DEP alone,
27 contained PVAP alone, four contained DEP in combin-
ation with PVAP and one contained DBP in combination
with DEP (Table 1). It should be noted that this list will
only contain those drugs registered on the eMC.
Whilst some companies provided maximum daily expos-
ure as requested, thus enabling direct comparison with
those set out in the draft guidelines, others did not specify
exposure levels but instead commented on how exposure
compared with the guidelines. In some instances, compan-
ies stipulated the amount of phthalate present in a single
unit of the medicine, thus requiring the authors to calculate
the maximum daily exposure based on maximum indicated
dose as per the ‘summary of product characteristics’ (SPC).
There were five cases where companies stated that they
were unable to quantify (UTQ) exposure and for 11 prod-
ucts, companies refused to declare (RTD). Remaining com-
panies provided no response (NR) at all which amounted to
12 products. Responses are summarised in Table 1, how-
ever, we were unable to include the phthalate content for
23 products because either the licence holder refused to de-
clare or provided no response.
The proposed permitted daily exposures (PDE) in the
EMA guidance equates to < 0.7 mg for DBP, 280 mg for
DEP and 140 mg for PVAP, for an individual with 70 kg
body weight.
Phthalate in tablet/capsule logo ink
For some preparations, the phthalate was contained in the
tablet/capsule logo ink on the surface of the dosage
formulation. In all of these preparations, the phthalate was
PVAP. For those companies who responded, the level of
PVAP in the ink in each preparation was below proposed
EMA PDE in all products. In some cases, the manufac-
turer declared that the phthalate content was so low per
dosage form that it was negligible or too low to measure
accurately.
Phthalate in tablet/capsule/liquid formulation
Where the phthalate was contained as an excipient
within the dosage form, the level of phthalate varied
considerably. The EMA proposes that the presence in
medicinal products of DBP, DEP or PVAP at levels giv-
ing rise to daily exposures above the PDEs may be ac-
cepted as exceptions, on a case-by-case basis taking into
consideration the intended patient population, the dis-
ease seriousness and the presence (or not) of alternative
treatment options. Furthermore, the EMA also proposes
that in severe or terminal disease conditions, the strict
application of the PDE may not be considered necessary
for DBP, DEP or PVAP-containing medicinal products,
where the risk of reproductive and developmental tox-
icity is outweighed by the benefits of treatment for
patients.
Consequently, the drugs were assessed in terms of
whether or not they are used acutely or chronically.
Where a drug may be used in either an acute or a
chronic condition, it was categorised as “chronicd”, due
to the possibility that the drug may be prescribed on a
long-term basis. Drugs were also categorised according
to whether or not they are licensed for use in pregnancy.
The SPC for some drugs advises caution in pregnancy or
the drug may be used where the benefit outweighs the
risk. For both of these categories, drugs were described
as “benefit > risk” (Table 1).
Where the licence holder supplied information regard-
ing DBP content, the level was above the proposed EMA
PDE of 0.7 mg for 70 kg body weight in Asacol 800 mg
MR (Warner Chilcott UK Ltd) and Vivotif (Crucell Italy
S.r.l), the levels being 48 mg and 8 mg, respectively, at
the maximum daily dose.
For DEP, the proposed EMA PDE is 280 mg per 70 kg
body weight. Where the licence holder supplied infor-
mation, this level was not exceeded at maximum daily
dose in the DEP-containing products.
The proposed EMA PDE for PVAP is 140 mg per 70 kg
body weight. There were two PVAP-containing products
where the level exceeded this. These were Prednisolone
2.5 mg Gastro-resistant Tablets and Prednisolone 5 mg
Gastro-resistant Tablets (Actavis UK Ltd), where the levels
at the maximum licensed daily dose were 288 and 144 mg,
respectively.
Four preparations contained a combination of DEP
and PVAP. Of these, Epilim 200 Gastro-resistant Tablets
Fig. 1 Algorithm for using the eMC to identify which UK licensed
medicines contain at least one of the three precautionary phthalates,
DBP, DEP and PVAP, named in the draft EMA guidelines on the use of
phthalates as excipients in human medicinal products
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Table 1 UK licensed medicines that contain DBP, DEP and/or PVAP and respective maximum daily exposures relative to proposed EMA guidelines










Phthalate in tablet/capsule/liquid formulation
Asacol 800 mg MR Tablets (mesalazine) Warner Chilcott UK Ltd DBP 8.00c 4.8 mg 48.00 Chronic Benefit>Risk
Coracten XL 30 mg (Nifedipine) UCB Pharma Ltd DBP 0.14 90 mg 0.42 Chronic No
Coracten XL 60 mg (Nifedipine) UCB Pharma Ltd DBP 0.28 90 mg 0.28 Chronic No
Occlusal (Salicylic acid) Alliance Pharmaceuticals DBP N/A RTD RTD Acute Benefit>Risk
Timodine Cream (Nystatin, Dimeticone,
Hydrocortisone & Benzalkonium Chloride)
Alliance Pharmaceuticals DBP N/A RTD RTD Acute No
Vivotif (Salmonella enterica serovar Typhi) Crucell Italy S.r.l DBP /
DEP
8.00 / 8.00 1 tablet 8.00 / 8.00 Acute Benefit>Risk
Kenzem 120 mg SR Capsules (Diltiazem
hydrochloride)
Kent Pharmaceuticals DEP NR 480 mg NR Chronic No
Kenzem 90 mg SR Capsules (Diltiazem
hydrochloride)
Kent Pharmaceuticals DEP NR 480 mg NR Chronic No
Kenzem 60 mg SR Capsules (Diltiazem
hydrochloride)
Kent Pharmaceuticals DEP NR 480 mg NR Chronic No
Omeprazole 40 mg Gastro-resistant Capsules, Hard
(Omeprazole)
Accord Healthcare Ltd DEP 0.15 120 mg 0.45 Chronicd Yes
Omeprazole 20 mg Gastro-resistant Capsules, Hard
(Omeprazole)
Accord Healthcare Ltd DEP 0.15 120 mg 0.90 Chronicd Yes
Reminyl XL 24 mg Prolonged Release Capsules
(Galantamine)
Shire Pharmaceuticals Ltd DEP NR 24 mg NR Chronic Benefit>Risk
Reminyl XL 16 mg Prolonged Release Capsules
(Galantamine)
Shire Pharmaceuticals Ltd DEP NR 24 mg NR Chronic Benefit>Risk
Reminyl XL 8 mg Prolonged Release Capsules
(Galantamine)
Shire Pharmaceuticals Ltd DEP NR 24 mg NR Chronic Benefit>Risk




DEP 0.95 150 mg 1.90 Acute No
Surgical Spirit BP (Virgin castor oil & Methyl salicylate Thornton & Ross Ltd DEP N/A N/A UTQ Acute Benefit>Risk




DEP RTD 400 mg RTD Chronic Benefit>Risk




DEP RTD 400 mg RTD Chronic Benefit>Risk




DEP RTD 400 mg RTD Chronic Benefit>Risk




DEP RTD 400 mg RTD Chronic Benefit>Risk


















Table 1 UK licensed medicines that contain DBP, DEP and/or PVAP and respective maximum daily exposures relative to proposed EMA guidelines (Continued)
Volsaid Retard 75 mg Tablets (Diclofenac Sodium) Chiesi Ltd DEP 0.95 150 mg 1.90 Acute No
Boots Constipation Relief Tablets 40s (Bisacodyl) Dr. Reddy’s Laboratories
(UK) Ltd
DEP NR 2 tablets NR Acute No




2.31 / 23.31 2500 mg 11.55 / 116.55 Chronic No




1.23 / 12.43 2500 mg 14.76 / 149.16 Chronic No






2.31 / 23.31 2500 mg 11.55 / 116.55 Chronic No






1.23 / 12.43 2500 mg 14.76 / 149.16 Chronic No
Boots Alternatives Laxative Tablets (Senna, Aloin,
Cascara bark extract)
G.R. Lane Health Products
Ltd
PVAP 2.10 2 tablets 4.20 Acute No
Boots Period Pain Relief 250 mg Gastro-resistant Tab-
lets (Naproxen)
Teva UK Ltd PVAP NR 500 mg NR Acute No
Deltacortril 2.5 mg Gastro-resistant Tablets
(Prednisolone)
Alliance Pharmaceuticals PVAP RTD 60 mg RTD Chronicd Benefit>Risk
Deltacortril 5 mg Gastro-resistant Tablets
(Prednisolone)
Alliance Pharmaceuticals PVAP RTD 60 mg RTD Chronicd Benefit>Risk
Disipal 50 mg Tablets (Orphenadrine hydrochloride) Astellas Pharma Ltd PVAP 17.30 400 mg 138.40 Chronic Benefit>Risk
Feminax Ultra 250 mg Gastro-resistant Tablets
(Naproxen)
Teva UK Ltd PVAP NR 750 mg NR Acute No
Ferrous Gluconate 300 mg Tablets (Ferrous
gluconate)
Kent Pharmaceuticals PVAP NR 1800 mg NR Chronicd Yes
Nardil 15 mg Tablets (Phenelzine) Archimedes Pharma UK
Ltd
PVAP 1.42 90 mg 8.52 Chronic No
Prednisolone 5 mg Gastro-resistant Tablets
(Prednisolone)
Actavis UK Ltd PVAP 12.00 60 mg 144.00 Chronicd Benefit>Risk
Prednisolone 2.5 mg Gastro-resistant Tablets
(Prednisolone)
Actavis UK Ltd PVAP 12.00 60 mg 288.00 Chronicd Benefit>Risk
Pancrex Granules (Pancreatin) Essential Pharmaceuticals
Ltd
PVAP RTD variablea RTD Chronic Benefit>Risk
Pancrex V Tablets (Pancreatin) Essential Pharmaceuticals
Ltd
PVAP RTD variablea RTD Chronic Benefit>Risk
Pancrex V Forte Tablets (Pancreatin) Essential Pharmaceuticals
Ltd
PVAP RTD variablea RTD Chronic Benefit>Risk
Phthalate in tablet/capsule logo ink
Aloxi 500 μg Soft Capsules (Palonosetron) Sinclair IS Pharma PVAP UTQ 500 μg UTQ Acute No
Amitiza 24 μg Soft Capsules (Lubiprostone) Sucampo Pharma Europe
Ltd


















Table 1 UK licensed medicines that contain DBP, DEP and/or PVAP and respective maximum daily exposures relative to proposed EMA guidelines (Continued)




PVAP <0.01 1200 mg 0.03 Acute No
Anadin Ultra/LiquiFast 200 mg Capsules (Aspirin) Pfizer Consumer
Healthcare
PVAP <0.01 1200 mg 0.05 Acute No
Aptivus 250 mg soft Capsules (Tipranavir) Boehringer Ingelheim Ltd PVAP UTQ 1000 mg UTQ Chronic Benefit>Risk
Benadryl Allergy Liquid Release 10 mg Capsules
(Certirizine dihydrochloride)
McNeil Products Ltd PVAP 1.00 10 mg 1 Chronicd Benefit>Risk
Nurofen Express 200 mg Liquid Capsules (Ibuprofen) Reckitt Benckiser
Healthcare (UK) Ltd
PVAP NR 1200 mg NR Acute No
Nurofen Express 400 mg Liquid Capsules (Ibuprofen) Reckitt Benckiser
Healthcare (UK) Ltd
PVAP NR 1200 mg NR Acute No
Targretin 75 mg Capsules (Bexarotene) Eisai Ltd PVAP UTQ 21 capsulesb UTQ Acute No
Xtandi 40 mg Soft Capsules (Enzalutamide) Astellas Pharma Ltd PVAP UTQ 160 mg UTQ Acute No
Zemplar Soft Capsules 2 μg (Paricalcitol) AbbVie Ltd PVAP 0.86 32 μg 13.76 Chronic Benefit>Risk
Zemplar Soft Capsules 1 μg (Paricalcitol) AbbVie Ltd PVAP 0.86 32 μg 27.52 Chronic Benefit>Risk
All calculations are based on the maximum licensed dose. If a drug has multiple indications, the indication with the highest dose was used for the calculation. For drugs that cannot be given at the maximum dose
due to their dose increment, (i.e. sodium valproate 200 mg – max dose 2500 mg), the maximum achievable dose within the product license was used
UTQ denotes unable to quantify, RTD denotes licence holder refused to declare, NR denotes no response
a Dosing regime of Pancrex is dependent on frequency of meals/snacks
b Based on a dose of 650 mg/m2/day for a person with a body surface area of 2.38–2.62 m2
c Information in the public domain [26, 27], license holder refused to confirm


















(Sanofi) and Zentiva 200 mg Gastro-resistant Tablets
(Winthrop Pharmaceuticals UK Limited) contained a
level of PVAP that was above the EMA PDE. The PVAP




The aim of this study was to identify which UK licensed
medicines are likely to be affected by proposed EMA
guidelines on the use of phthalates as excipients in human
medicinal products. Although we attempted to identify as
many phthalate-containing preparations as possible by
reviewing SPCs, this list cannot be considered exhaustive.
For 23 products, the licence holder refused to declare the
phthalate content or gave no response. At face value, it ap-
peared that many medicines would be impacted by the
recommendations as 54 medicines were identified as con-
taining the precautionary phthalates DBP, DEP and PVAP,
named in the guidelines. However, for those medicines
where companies responded, once maximum daily phthal-
ate exposures were established, only six branded medi-
cines, namely Asacol 800 mg MR (Warner Chilcott UK
Ltd), Epilim 200 Gastro-resistant Tablets (Sanofi), Prednis-
olone 2.5 and 5 mg Gastro-resistant Tablets (Actavis UK
Ltd), Vivotif (Crucell Italy S.r.l), and Zentiva 200 mg
Gastro-resistant Tablets (Winthrop Pharmaceuticals UK
Limited), were identified as exceeding the EMA’s proposed
recommendations. Thus, this study will help to appease
those concerned about the implications of enforcement of
these guidelines.
Strengths and limitations
To the authors’ knowledge, this study has provided the
first review of the presence of phthalates in UK licenced
medications. Furthermore, it has identified, where pos-
sible, which phthalate-containing medications will be af-
fected by EMA guidance once it comes into practice. By
virtue of the limited information in the public domain
and the proprietary nature of drug formulations, infor-
mation on the concentration of phthalates was limited
to only 57 % of the drugs identified. This highlights the
potential difficulty in clinical practice when undertaking
a risk/benefit approach in the preceding 3 years before
the enforcement of this guidance. In addition, not all
SPC’s are available on the eMC, further hindering the
ability of making an informed decision in certain patient
populations.
Conclusion
For those medicines identified as exceeding the EMA’s
recommendations, this study has highlighted the need to
instigate a risk-benefit review, particularly in patients of
childbearing age and/or with chronic conditions. To
facilitate this process, the EMA, suggests taking into ac-
count factors such as the presence of non-phthalate con-
taining alternatives, the intended patient population and
the severity of the disease being treated.
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